Literature DB >> 14997272

Nicotine improves delayed recognition in schizophrenic patients.

Carol S Myers1, Olalla Robles, A Nancy Kakoyannis, Jay D Sherr, Matthew T Avila, Teresa A Blaxton, Gunvant K Thaker.   

Abstract

RATIONALE: Nicotine has been shown to enhance some aspects of memory, attention and cognition in normal subjects and in some patient populations such as Alzheimer's and Parkinson's disease groups.
OBJECTIVES: Memory disorders are consistently observed in schizophrenic patients, so it is of interest to determine whether nicotine might improve memory performance in these patients.
METHODS: Delayed recognition was assessed using yes/no recognition of visuospatial designs. Working memory was assessed in a delayed match-to-sample paradigm using unfamiliar faces. Nicotine (1.0 mg delivered via nasal spray) was administered to schizophrenic patients and normal volunteers prior to testing in the nicotine condition. Results were compared to a baseline condition in which no nicotine was given.
RESULTS: On both tasks, normal volunteers performed better overall than schizophrenic patients. Significant improvement following nicotine administration was obtained only on the delayed recognition task and only for the subset of schizophrenic patients who were smokers. This improvement reflected a reduction in false alarm rates in the nicotine condition; hit rates were unaffected by nicotine.
CONCLUSIONS: These results suggest that nicotine enhances delayed recognition memory in schizophrenic patients who smoke, but that similar performance enhancement is not observed for working memory.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14997272     DOI: 10.1007/s00213-003-1764-8

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  41 in total

1.  Beneficial effects of nicotine administered prior to a delayed matching-to-sample task in young and aged monkeys.

Authors:  J J Buccafusco; W J Jackson
Journal:  Neurobiol Aging       Date:  1991 May-Jun       Impact factor: 4.673

2.  Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers.

Authors:  A Olincy; D A Young; R Freedman
Journal:  Biol Psychiatry       Date:  1997-07-01       Impact factor: 13.382

Review 3.  Schizophrenia and nicotinic receptors.

Authors:  R Freedman; L E Adler; P Bickford; W Byerley; H Coon; C M Cullum; J M Griffith; J G Harris; S Leonard; C Miller
Journal:  Harv Rev Psychiatry       Date:  1994 Nov-Dec       Impact factor: 3.732

Review 4.  Increased regional cerebral glucose metabolism and semantic memory performance in Alzheimer's disease: a pilot double blind transdermal nicotine positron emission tomography study.

Authors:  R W Parks; R E Becker; R F Rippey; D G Gilbert; J R Matthews; E Kabatay; C S Young; C Vohs; V Danz; P Keim; G T Collins; S S Zigler; P G Urycki
Journal:  Neuropsychol Rev       Date:  1996-06       Impact factor: 7.444

5.  The effects of nicotine upon memory and problem solving performance.

Authors:  M P Dunne; D Macdonald; L R Hartley
Journal:  Physiol Behav       Date:  1986

6.  Normalization of auditory physiology by cigarette smoking in schizophrenic patients.

Authors:  L E Adler; L D Hoffer; A Wiser; R Freedman
Journal:  Am J Psychiatry       Date:  1993-12       Impact factor: 18.112

Review 7.  Schizophrenia, sensory gating, and nicotinic receptors.

Authors:  L E Adler; A Olincy; M Waldo; J G Harris; J Griffith; K Stevens; K Flach; H Nagamoto; P Bickford; S Leonard; R Freedman
Journal:  Schizophr Bull       Date:  1998       Impact factor: 9.306

8.  Scopolamine reversal of nicotine enhanced delayed matching-to-sample performance in monkeys.

Authors:  A V Terry; J J Buccafusco; W J Jackson
Journal:  Pharmacol Biochem Behav       Date:  1993-08       Impact factor: 3.533

9.  Nicotine enhances Morris water maze performance of young and aged rats.

Authors:  D J Socci; P R Sanberg; G W Arendash
Journal:  Neurobiol Aging       Date:  1995 Sep-Oct       Impact factor: 4.673

Review 10.  Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings.

Authors:  G W Dalack; D J Healy; J H Meador-Woodruff
Journal:  Am J Psychiatry       Date:  1998-11       Impact factor: 18.112

View more
  33 in total

Review 1.  The treatment of cognitive impairment in schizophrenia.

Authors:  Donald C Goff; Michele Hill; Deanna Barch
Journal:  Pharmacol Biochem Behav       Date:  2010-11-27       Impact factor: 3.533

Review 2.  Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models.

Authors:  L Lyon; L M Saksida; T J Bussey
Journal:  Psychopharmacology (Berl)       Date:  2011-11-10       Impact factor: 4.530

3.  Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder.

Authors:  L Elliot Hong; Gunvant K Thaker; Robert P McMahon; Ann Summerfelt; Jill Rachbeisel; Rebecca L Fuller; Ikwunga Wonodi; Robert W Buchanan; Carol Myers; Stephen J Heishman; Jeff Yang; Adrienne Nye
Journal:  Arch Gen Psychiatry       Date:  2011-08-01

4.  The antisaccade task as an index of sustained goal activation in working memory: modulation by nicotine.

Authors:  Nicola Rycroft; Samuel B Hutton; Jennifer M Rusted
Journal:  Psychopharmacology (Berl)       Date:  2006-08-01       Impact factor: 4.530

Review 5.  Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.

Authors:  Ann Olincy; Karen E Stevens
Journal:  Biochem Pharmacol       Date:  2007-07-17       Impact factor: 5.858

Review 6.  Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function.

Authors:  Edward D Levin; Amir H Rezvani
Journal:  Biochem Pharmacol       Date:  2007-07-20       Impact factor: 5.858

7.  BRAIN MYELINATION IN PREVALENT NEUROPSYCHIATRIC DEVELOPMENTAL DISORDERS: PRIMARY AND COMORBID ADDICTION.

Authors:  George Bartzokis
Journal:  Adolesc Psychiatry       Date:  2005

8.  Initial phase 2 trial of a nicotinic agonist in schizophrenia.

Authors:  Robert Freedman; Ann Olincy; Robert W Buchanan; Josette G Harris; James M Gold; Lynn Johnson; Diana Allensworth; Alejandrina Guzman-Bonilla; Bettye Clement; M Patricia Ball; Jay Kutnick; Vicki Pender; Laura F Martin; Karen E Stevens; Brandie D Wagner; Gary O Zerbe; Ferenc Soti; William R Kem
Journal:  Am J Psychiatry       Date:  2008-04-01       Impact factor: 18.112

9.  Long-term improvements in sensory inhibition with gestational choline supplementation linked to α7 nicotinic receptors through studies in Chrna7 null mutation mice.

Authors:  Karen E Stevens; Kevin S Choo; Jerry A Stitzel; Michael J Marks; Catherine E Adams
Journal:  Brain Res       Date:  2014-01-23       Impact factor: 3.252

10.  Cognitive performance and cigarette smoking in first-episode psychosis.

Authors:  Arantzazu Zabala; José Ignacio Eguiluz; Rafael Segarra; Sonsoles Enjuto; Jesús Ezcurra; Ana González Pinto; Miguel Gutiérrez
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-06-26       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.